{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:13:10Z","timestamp":1786975990501,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd012722","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000}}],"reference-count":135,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012722.pub2","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:24:47Z","timestamp":1547771087000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Methotrexate for psoriatic arthritis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Tom D","family":"Wilsdon","sequence":"first","affiliation":[{"name":"Royal Adelaide Hospital and University of Adelaide; Department of Rheumatology; Port Rd Adelaide South Australia Australia 5000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L","family":"Whittle","sequence":"additional","affiliation":[{"name":"The Queen Elizabeth Hospital and University of Adelaide; Department of Rheumatology; 28 Woodville Road Woodville South Australia Australia 5011"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilenka RJ","family":"Thynne","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre and Flinders University; Department of Clinical Pharmacology; Flinders Drive Bedford Park South Australia Australia 5042"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arduino A","family":"Mangoni","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre and Flinders University; Department of Clinical Pharmacology; Flinders Drive Bedford Park South Australia Australia 5042"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0001|cit1","first-page":"51","article-title":"Efficacy and safety of leflunomide in psoriatic arthritis","volume":"24","author":"Asaduzzaman","year":"2014","journal-title":"Journal of the Pakistan Association of Dermatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0002|cit2","first-page":"743","article-title":"Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients","volume":"189","author":"Black","year":"1964","journal-title":"Journal of the American Medical Association"},{"issue":"5","key":"10.1002\/14651858.CD012722.pub2-BIB0003|cit3","first-page":"54","article-title":"The comparative efficacy of slow-acting (basic) preparations in psoriatic arthritis","volume":"64","author":"Burdeinyi","year":"1992","journal-title":"Terapevticheskii Arkhiv"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD012722.pub2-BIB0004|cit4","first-page":"iii89","article-title":"Quality of life in psoriatic arthritis: comparative results with rheumatoid arthritis using SF36 in trials using methotrexate","volume":"41","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0005|cit5","first-page":"664","article-title":"Methotrexate is not disease modifying in psoriatic arthritis: the MIPA trial","volume":"62","author":"Kingsley","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012722.pub2-BIB0007|cit7","first-page":"i1","article-title":"Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required","volume":"49","author":"Kingsley","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1002\/14651858.CD012722.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa","year":"2008","journal-title":"Clinical Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD012722.pub2-BIB0009|cit9","first-page":"589","article-title":"Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study","volume":"13","author":"Spadaro","year":"1995","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD012722.pub2-BIB0011|cit11","first-page":"570","article-title":"A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis","volume":"48","author":"Zhang","year":"2009","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0012|cit12","first-page":"241","article-title":"Long term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/ard.2010.130864","article-title":"Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study","volume":"70","author":"Atzeni","year":"2011","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Annals of Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1185\/03007997709110154","article-title":"Comparison of intra-articular methotrexate with intra-articular triamcinolone hexacetonide by thermography","volume":"5","author":"Bird","year":"1977","journal-title":"Current Medical Research and Opinion"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0016|cit16","first-page":"31","article-title":"Combination therapies in spondyloarthropathies","volume":"50","author":"Calguneri","year":"2004","journal-title":"Kobe Journal of Medical Science"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0017|cit17","first-page":"S346","article-title":"Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome","volume":"65","author":"Coates","year":"2013","journal-title":"Arthitis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0140-6736(14)60299-3","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a multicentre, open-label, randomised controlled trial","volume":"383","author":"Coates","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2015-eular.5196","article-title":"Methotrexate in early psoriatic arthritis - open label data from the TICOPA study","volume":"74","author":"Coates","year":"2015","journal-title":"Annals of Rheumatic Diseases"},{"issue":"10012","key":"10.1002\/14651858.CD012722.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised, controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate in the tight control in psoriatic arthritis study","volume":"43","author":"Coates","year":"2016","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD012722.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/annrheumdis-2017-211137","article-title":"The dynamics of response as measured by multiple composite outcome tools in the tight control of inflammation in early psoriatic arthritis (TICOPA) trial","volume":"76","author":"Coates","year":"2017","journal-title":"Annals of Rheumatic Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012722.pub2-BIB0023|cit23","first-page":"42","article-title":"Secukinumab, a monoclonal antibody to interleukin-17a, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study","volume":"45","author":"Collins","year":"2015","journal-title":"Internal Medicine Journal"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0024|cit24","first-page":"S154","article-title":"Response to etanercept with or without methotrexate combination therapy in patients with psoriatic arthritis","volume":"65","author":"Combe","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD012722.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","article-title":"Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials","volume":"43","author":"Combe","year":"2016","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/ard.2008.091900","article-title":"Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic antitumour necrosis factor alpha","volume":"67","author":"Conti","year":"2008","journal-title":"Annals of Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/rheumatology\/13.3.120","article-title":"Treatment of psoriatic arthropathy with either azathioprine or methotrexate","volume":"13","author":"Feldges","year":"1974","journal-title":"Rheumatology and Rehabilitation"},{"issue":"6","key":"10.1002\/14651858.CD012722.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2004.024463","article-title":"A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis","volume":"64","author":"Fraser","year":"2005","journal-title":"Annals of Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD012722.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3899\/jrheum.141010","article-title":"Validation of the OMERACT psoriatic arthritis magnetic resonance imaging score (PsAMRIS) for the hand and foot in a randomized placebo-controlled trial","volume":"42","author":"Glinatsi","year":"2015","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0030|cit30","first-page":"AB270","article-title":"Secukinumab improves signs and symptoms of psoriatic arthritis: results of phase 3 FUTURE 2 study stratified by concomitant methotrexate use","volume":"1","author":"Gottlieb","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0031|cit31","first-page":"AB271","article-title":"Secukinumab inhibits radiographic progression in patients with psoriatic arthritis: results of phase 3 FUTURE 1 study stratified by concomitant methotrexate use","volume":"1","author":"Gottlieb","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD012722.pub2-BIB0032|cit32","first-page":"2369","article-title":"Is methotrexate really effective in patients with psoriatic arthritis?","volume":"22","author":"Goupille","year":"1995","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.37.4.351","article-title":"Intra-articular methotrexate. Clinical and laboratory study in rheumatoid and psoriatic arthritis","volume":"37","author":"Hall","year":"1978","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cyto.2010.07.095","article-title":"Comparison study of recombinant human interleukin-1 receptor antagonist for treating psoriatic and rheumatoid arthritis","volume":"52","author":"Ischenko","year":"2010","journal-title":"Cytokine"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/ard.2005.040196","article-title":"Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Annals of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0037|cit37","first-page":"1736","article-title":"Golimumab treatment inhibits progression in joint damage in patients with psoriatic arthritis regardless of baseline disease severity","volume":"39","author":"Kavanaugh","year":"2012","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD012722.pub2-BIB0038|cit38","first-page":"1724","article-title":"The effect of certolizumab pegol on skin manifestations of psoriatic arthritis over 4 years of treatment","volume":"68","author":"Khraishi","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0039|cit39","first-page":"116","article-title":"Methotrexate and cyclosporine combined therapy in severe psoriatic arthritis. A pilot study","volume":"186","author":"Mazzanti","year":"1994","journal-title":"Acta Dermato-Venerologica (Stockholm)"},{"issue":"9999","key":"10.1002\/14651858.CD012722.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin 17a monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0041|cit41","first-page":"S423","article-title":"A phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakinumab, an anti-IL-6 monoclonal antibody, in adults with active psoriatic arthritis","volume":"66","author":"Mease","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD012722.pub2-BIB0042|cit42","first-page":"1366","article-title":"Abatacept in the treatment of active psoriatic arthritis: 24-week results from a phase III study","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0043|cit43","first-page":"AB235","article-title":"Adalimumab is associated with reduced risk of joint-related signs and symptoms compared with methotrexate in patients with moderate to severe psoriasis","volume":"1","author":"Merola","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0044|cit44","first-page":"163","article-title":"Observation of efficacy of biological combined with different DMARDs against psoriatic arthritis","volume":"19","author":"Min","year":"2016","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0045|cit45","first-page":"312","article-title":"Clinical trial of amethopterin (methotrexate) in psoriatic and rheumatoid arthritis (preliminary report)","volume":"5","author":"O'Brien","year":"1962","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0046|cit46","first-page":"1780","article-title":"Infliximab plus methotrexate significantly improves rates of remission for methotrexate naive psoriatic arthritis (PsA) patients compared to methotrexate alone: the RESPOND trial","volume":"60","author":"Raffayova","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0047|cit47","first-page":"1256","article-title":"Infliximab plus methotrexate significantly improves synovitis and psoriatic lesions in methotrexate naive psoriatic arthritis (PsA) patients: results of the RESPOND trial","volume":"60","author":"Raffayova","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0048|cit48","first-page":"AB124","article-title":"Adalimumab response is consistent across subgroups of patients with moderate to severe psoriasis: subanalysis of the CHAMPION study","volume":"1","author":"Saurah","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD012722.pub2-BIB0049|cit49","first-page":"780","article-title":"Oral apremilast is effective with and without concomitant methotrexate therapy in the treatment of subjects with active psoriatic arthritis","volume":"63","author":"Schett","year":"2011","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0050|cit50","first-page":"136","article-title":"Oral apremilast is effective in the treatment of subjects with active psoriatic arthritis with and without concomitant methotrexate therapy","volume":"71","author":"Schett","year":"2012","journal-title":"Zeithschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0051|cit51","first-page":"S607","article-title":"Abatacept improves synovitis as assessed by magnetic resonance imaging (MRI) in psoriatic arthritis - preliminary analysis from a single centre, placebo-controlled, crossover study","volume":"66","author":"Szentpetery","year":"2015","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0052|cit52","unstructured":"A multicenter, double-blind, randomized controlled study of etanercept and methotrexate in combination or as monotherapy in subjects with psoriatic arthritis Ongoing study"},{"issue":"2-3","key":"10.1002\/14651858.CD012722.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0162-3109(00)00184-3","article-title":"Methotrexate use in rheumatoid arthritis. A clinician's perspective","volume":"47","author":"Alarc\u00f3n","year":"2000","journal-title":"Immunopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Research and Therapy"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/art.22800","article-title":"Improved survival in psoriatic arthritis with calendar time","volume":"56","author":"Ali","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0057|cit57","unstructured":"Dr. Christopher Cates EBM website. www.nntonline.net Visual Rx 2008"},{"issue":"12","key":"10.1002\/14651858.CD012722.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD012722.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/art.34536","article-title":"Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"64","author":"Coates","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD012722.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/rheumatology\/kew390","article-title":"New GRAPPA and EULAR recommendations for the management of psoriatic arthritis","volume":"56","author":"Coates","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1136\/annrheumdis-2017-211137","article-title":"The dynamics of response as measured by multiple composite outcome tools in the tight control of inflammation in early psoriatic arthritis (TICOPA) trial","volume":"76","author":"Coates","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"h1269","DOI":"10.1136\/bmj.h1269","article-title":"Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials","volume":"350","author":"Conway","year":"2015","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-0348-8452-5_5","article-title":"Treatment of inflammatory disease","volume-title":"Methotrexate","author":"Cronstein","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6 Suppl 28","key":"10.1002\/14651858.CD012722.pub2-BIB0067|cit67","first-page":"S76","article-title":"Methotrexate in psoriatic arthritis","volume":"20","author":"Cutolo","year":"2002","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0068|cit68","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) Chapter 9. Analysing data and undertaking meta-analyses. In Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011) Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.berh.2012.01.003","article-title":"Psoriatic arthritis","volume":"26","author":"Duarte","year":"2012","journal-title":"Best Practice and Research Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD012722.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis - oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and metaanalyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"238","key":"10.1002\/14651858.CD012722.pub2-BIB0074|cit74","first-page":"127","article-title":"Psoriatic arthritis (PSA) - an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Quarterly Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012722.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012722.pub2-BIB0076|cit76","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0077|cit77","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0079|cit79","unstructured":"McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org GRADEpro Guideline Development Tool 2015"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"British Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD012722.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Care and Research"},{"issue":"9","key":"10.1002\/14651858.CD012722.pub2-BIB0082|cit82","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0083|cit83","first-page":"472","article-title":"Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions","volume":"35","author":"Helliwell","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0085|cit85","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0086|cit86","unstructured":"Higgins JPT Deeks JJ editor(s) Chapter 7. Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0087|cit87","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000212","article-title":"Interventions for treating psoriatic arthritis","author":"Jones","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumour necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD012722.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD012722.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","article-title":"Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis","volume":"43","author":"Kosinski","year":"2000","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD012722.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Archives of Neurology"},{"issue":"5 Suppl 39","key":"10.1002\/14651858.CD012722.pub2-BIB0093|cit93","first-page":"S188","article-title":"A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases","volume":"23","author":"Kvien","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/028418517701800415","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiologica: Diagnosis"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","article-title":"Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis","volume":"21","author":"Li","year":"2015","journal-title":"Journal of Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD012722.pub2-BIB0096|cit96","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000957.pub2","article-title":"Methotrexate for treating rheumatoid arthritis","author":"Lopez-Olivo","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2133.2003.05492.x","article-title":"Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials","volume":"149","author":"McKenna","year":"2003","journal-title":"British Journal of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD012722.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD012722.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD012722.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","article-title":"Updating the Psoriatic Arthritis (PsA) Core Domain Set: a report from the PsA Workshop at OMERACT 2016","volume":"44","author":"Orbai","year":"2017","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD012722.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780261107","article-title":"Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire","volume":"26","author":"Pincus","year":"1983","journal-title":"Arthritis and Rheumatism"},{"issue":"5 Suppl 93","key":"10.1002\/14651858.CD012722.pub2-BIB0104|cit104","first-page":"S82","article-title":"Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?","volume":"33","author":"Pincus","year":"2015","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0106|cit106","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0110|cit110","unstructured":"Sch\u00fcnemann H Oxman AD Vist GE Higgins JBT Deeks JJ Glasziou P editor(s) Chapter 12. Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org."},{"key":"10.1002\/14651858.CD012722.pub2-BIB0111|cit111","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH editor(s) Chapter 11. Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/rheumatology\/16.4.257","article-title":"Measurement of functional capacity with visual analogue scales","volume":"16","author":"Scott","year":"1977","journal-title":"Rheumatology and Rehabilitation"},{"issue":"6","key":"10.1002\/14651858.CD012722.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD012722.pub2-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000951.pub2","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","author":"Shea","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","article-title":"The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue","volume":"39","author":"Smets","year":"1995","journal-title":"Journal of Psychosomatic Research"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0118|cit118","unstructured":"Sterne JAC Egger M Moher D editor(s) Chapter 10. Addressing reporting biases. In Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Stolwijk C Van Onna M Boonen A Van Tubergen A The global prevalence of spondyloarthritis: a systematic review and meta-regression analysis Arthritis Care and Research 2016 1320 31 10.1002\/acr.22831","DOI":"10.1002\/acr.22831"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CCID.S90270","article-title":"Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis","volume":"8","author":"Truong","year":"2015","journal-title":"Clinical, Cosmetic and Investigational Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0124|cit124","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"Heijde","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD012722.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/art.10089","article-title":"Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?","volume":"46","author":"Doornum","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism criteria","volume":"39","author":"Gestel","year":"1996","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"e000025","DOI":"10.1136\/rmdopen-2014-000025","article-title":"What makes psoriatic and rheumatoid arthritis so different?","volume":"1","author":"Veale","year":"2015","journal-title":"RMD Open"},{"issue":"8","key":"10.1002\/14651858.CD012722.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3899\/jrheum.140259","article-title":"Work productivity loss and fatigue in psoriatic arthritis","volume":"41","author":"Walsh","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD012722.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/art.37723","article-title":"Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis","volume":"65","author":"Wasko","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD012722.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s003930170064","article-title":"A method to score radiographic change in psoriatic arthritis","volume":"60","author":"Wassenberg","year":"2001","journal-title":"Zeitschrift fu\u0308r Rheumatologie"},{"key":"10.1002\/14651858.CD012722.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health and Quality of Life Outcomes"},{"issue":"7","key":"10.1002\/14651858.CD012722.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012722","article-title":"Methotrexate for psoriatic arthritis","author":"Wilsdon","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012722.pub2-BIB0134|cit134","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound causation studies in EMBASE","volume":"94","author":"Wong","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"2","key":"10.1002\/14651858.CD012722.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/00015550252948130","article-title":"Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study","volume":"82","author":"Zachariae","year":"2002","journal-title":"Acta Dermato-Venereologica"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012722.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T09:48:02Z","timestamp":1689241682000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012722.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012722.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]}}}